India’s Pricing Tussle Escalates After Regulator Names “Overcharging” Firms

Tensions between India’s apex drug pricing authority and industry appear set to intensify after the regulator flagged up over 600 “suspected” cases of overcharging. The way forward for both sides is probably only through constructive dialogue and a less combative approach. The Pink Sheet delves into the key sticking points around the standoff.